Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: Implications for specific immunotherapy
- 1 May 2006
- Vol. 67 (5) , 955-959
- https://doi.org/10.1016/j.urology.2005.11.052
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The expression and significance of survivin mRNA in urinary bladder carcinomasZeitschrift für Krebsforschung und Klinische Onkologie, 2004
- Urine Detection of Survivin is a Sensitive Marker for the Noninvasive Diagnosis of Bladder CancerJournal of Urology, 2004
- Expression of Survivin, a Novel Inhibitor of Apoptosis, in Superficial Transitional Cell Carcinoma of the BladderJournal of Urology, 2004
- Effect of Intravesical Treatment of Transitional Cell Carcinoma With Bacillus Calmette-Guerin and Mitomycin C on Urinary Survivin Levels and OutcomeJournal of Urology, 2003
- HLA class I antigen abnormalities and immune escape by malignant cellsSeminars in Cancer Biology, 2002
- The molecular basis and potential role of survivin in cancer diagnosis and therapyTrends in Molecular Medicine, 2001
- Urine Detection of Survivin and Diagnosis of Bladder CancerJAMA, 2001
- Tumor Content of the Antiapoptosis Molecule Survivin and Recurrence of Bladder CancerNew England Journal of Medicine, 1999
- IAP family proteins---suppressors of apoptosisGenes & Development, 1999
- A novel anti-apoptosis gene, survivin, expressed in cancer and lymphomaNature Medicine, 1997